November 17, 2010
Growth Factor Reverses Gum Tissue Loss On Teeth

Japanese researchers find that a growth factor helps to reverse the effect of periodontitis

In an article titled "FGF-2 Stimulates Periodontal Regeneration: Results of a Multicenter Randomized Clinical Trial," which is published in the International and American Associations for Dental Research's Journal of Dental Research, M. Kitamura, from Osaka University Graduate School of Dentistry, Japan, and a team of researchers conducted a human clinical trial to determine the safety and effectiveness of fibroblast growth factor-2 (FGF-2) for clinical application. This is the largest study to date in the field of periodontal regenerative therapy.

We really ought to have the ability to get receded gums to grow back onto teeth. This is one of many ways where if we could just instruct cells to do our bidding we could prevent or reverse a form of age-related decay in our bodies.

This research looks promising.

A randomized, double-masked, placebo-controlled clinical trial was conducted in 253 adults afflicted with periodontitis. Periodontal surgery was performed, during which one of three different doses of FGF-2 was randomly administered to localized bone defects. Each dose of FGF-2 showed significant superiority over the standard of care (vehicle alone (p < 0.01)) for the percentage of bone fill at 36 wks after administration, and the percentage peaked in the mid-dose FGF-2 group. These results strongly support the topical application of FGF-2 can be efficacious in the regeneration of human periodontal tissue that has been destroyed by periodontitis.

Share |      Randall Parker, 2010 November 17 10:49 PM  Biotech Teeth And Gums


Comments
Lou Pagnucco said at November 18, 2010 9:13 AM:

A quick, cursory web search leads to some papers which seem to show that FGF-2 repairs ligaments that anchor teeth also - which is not obvious from the abstract. Transplanted tissue that locally generates FGF-2 also appears to help regenerate damaged joint cartilage in some arthritic diseases.

It would be interesting to know if FGF-2 works synergistically with drugs that inhibit the enzymes (e.g., matrix metallo-proteases) that break down connective tissues, or with anti-inflammatory drugs.

PacRim Jim said at November 18, 2010 10:38 AM:

Put it in toothpaste. Gack!

Sheri said at November 19, 2010 3:50 PM:

Lots of people have gum loss from abrasion, orthodontics, trauma, and other factors besides periodontal disease. Not all have bone loss, either. I hope eventually gum tissue could be regenerated for everybody, which would prevent a lot of tooth loss.

georce said at November 19, 2010 4:53 PM:

Too late for me. I just had a big chunk of tissue carved out of my palate to rebuild my front gum line prior to receiving tooth implants. Guess how much fun that is.

Randall Parker said at November 20, 2010 11:34 AM:

Sheri,

Yes, gum tissue regeneration would help accident victims, assault victims, wounded soldiers, and others.

I also look forward to the ability to initiate the growth of new teeth. I happen to have a couple of front cracked teeth from stupid things I did as a kid. They've managed to stay together so far. But it would be great to grow replacements.

Lou,

FGF-2 for joints: We need ways to build up surfaces around elbows and especially knees. I am amazed at how many people I know in their 30s and 40s who have knee problems they can trace back to things they did (intense basketball or backpacking for example) their teens and 20s. We need ways to tell tissue to build up new surfaces.

bamboo said at November 23, 2010 3:17 PM:

from US company, Organogenesis, late 2009. a new treatment for receeding gums.

afaik, currently under consideration by fda

Company Applies Regenerative Medicine Expertise for New Therapeutic Class in Dentistry, Periodontology and Oral Surgery

Clinicians currently have limited options to correct gingival recession. Most commonly they perform a free gingival graft, in which tissue is taken from the roof of the mouth (palate) and is transplanted to the gum in order to prevent further recession. This procedure is performed approximately 500,000 times per year in the U.S. Drawbacks to free gingival graft procedures include pain and morbidity (at the site of the palate graft), insufficient tissue to treat all sites requiring treatment and often unappealing aesthetics due to poor color and texture match of the graft to the adjacent gums.

"We designed CelTx to address these shortcomings. Once approved, CelTx will allow a clinician to fully treat all compromised gums, will reduce patient pain and complications by eliminating the need for a graft, and provide a highly aesthetic clinical outcome,” continued Eklund. “We are looking forward to introducing what we believe will be a new therapeutic class in dentistry."


http://www.organogenesis.com/news/press_releases/press_release_ogn_files-21122009.html

bamboo said at May 9, 2011 2:16 PM:

update,
organogenesis still awaiting fda approval afaik.
stage three trials in place, not sure when will be completed.
this utube vid posted by the co. nov 2010.

http://www.youtube.com/watch?v=HA1kf1uKYvs

CelTx is a living cellular construct, designed to regenerate oral soft tissue.

bamboo said at March 29, 2012 6:18 AM:

at last...
ask your dentist about this new product...

"ORGANOGENESIS INC. ANNOUNCES FDA APPROVAL OF GINTUIT™ FOR ORAL SOFT TISSUE REGENERATION
FDA Approval Marks First-Ever CBER-Approved Allogeneic Cell-Based Product
Canton, Mass. – Monday, March 12, – Today Organogenesis Inc., a business leader in the regenerative medicine field, announced that the United States Food and Drug Administration (FDA) has approved GINTUIT™ (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen), a cell-based product that has been shown to predictably generate new and aesthetically appealing oral soft tissue (gum tissue).

The GINTUIT approval marks two important firsts: the first-ever approval of an allogeneic cell product via the Center for Biologics Evaluation and Research (CBER) arm of the FDA, and the first cell-based technology that is FDA-approved for use in the dental market.

"This FDA approval is a significant milestone for our company, for the FDA, and for the regenerative medicine and dental surgery fields," said Organogenesis President & CEO Geoff MacKay. "As a pioneer in regenerative medicine, Organogenesis continues to lead the way by ushering in a completely new therapeutic class in dentistry. Our second breakthrough cell-based product, GINTUIT will help dental surgeons generate new gum tissue for their patients without turning to palate graft surgery."

GINTUIT is a cellular sheet that contains human fibroblasts, keratinocytes, human extracellular matrix proteins and bovine collagen. These cells produce a wide array of cytokines and growth factors, signals that allow cells to communicate with each other. These proteins are important factors for the healing and regeneration of tissue.

"Anyone who has experienced the discomfort of palatal graft surgery will immediately recognize the benefits of a product that has been shown to generate new gum tissue, and importantly, does not require excision of tissue from the roof of a patient's mouth," continued Mr. MacKay."

http://www.organogenesis.com/news/press_releases/press_release_announces-03122012.html

tman said at December 2, 2012 3:07 AM:

Sorry to put a dampner on things, but if you read the small print :

"GINUIT is not intended to provide root coverage."

kenny siu said at June 9, 2015 12:28 PM:

wish for the day to come.
I am suffering from mild periodontal disease but my gum for some teeth has receded a lot after the periodontal treatment. I feel so upset to see all these holes every day every night...

Post a comment
Comments:
Name (not anon or anonymous):
Email Address:
URL:
Remember info?

                       
Go Read More Posts On FuturePundit
Site Traffic Info
The contents of this site are copyright ©